癌变·畸变·突变 ›› 2007, Vol. 19 ›› Issue (4): 280-284.doi: 10.3969/j.issn.1004-616x.2007.04.006

• 论著 • 上一篇    下一篇

ERK1/2_Sp1信号通路对肺癌细胞VEGF的调控作用

梁 璇 丁新民 霍艳英 潘兴斌 隋建丽 白 贝 徐勤枝 周平坤   

  1. 军事医学科学院放射与辐射医学研究所,北京
  • 收稿日期:2006-09-13 修回日期:2006-12-01 出版日期:2007-07-30 发布日期:2007-07-30

Role of ERK1/2_Sp1 in Regulation of VEGF Expression in Lung Cancer Cells

LIANG Xuan,DING Xin_min, HUO Yan_ying, PAN Xing_bin, SUI Jian_li, BAI Bei, XU Qin_zhi, ZHOU Pin_kun   

  1. Beijing Institute of Radiation Medicine, Beijing
  • Received:2006-09-13 Revised:2006-12-01 Online:2007-07-30 Published:2007-07-30

摘要: 背景与目的:了解ERK1/2_Sp1信号通路对肺癌细胞血管内皮生长因子(VEGF)基因的调控作用。 材料与方法: 采用激酶特异抑制剂PD98059抑制ERK1/2的活性,Western blot 检测ERK1/2的表达。RNA干扰技术沉默Sp1基因,Mercury 信号通路系统检测Sp1的转录活性。RT_PCR检测VEGF和Sp1基因的变化。 结果: ERK1/2激酶的活性几乎可被150 μmol/L PD98059完全抑制,ERK1/2激酶活性下调伴随VEGF的表达下降。PD98059下调Sp1转录因子的活性。Sp1基因沉默后VEGF的表达量下调。 结论: 在肺癌细胞中存在ERK1/2_Sp1_VEGF信号通路,ERK1/2激酶调控VEGF的表达可能部分依赖于转录因子Sp1的活性。

关键词: 肺癌, VEGF;ERK1/2激酶;Sp1

Abstract: BACKGROUND & AIM: To study the underlying molecular mechanisms by which ERK1/2 kinase modulated the expression of vascular endothelial cells growth factor (VEGF) in lung cancer cells. MATERIALS AND METHODS: PD98059, the special inhibitor of ERK1/2, was used to inhibit the phosphorylation of ERK1/2. Western blot was used to evaluate the expression of ERK1/2. Transcription factor Sp1 gene was silenced by small interfering RNA technology. SEAP assay was used to detect the transcription activity of Sp1. RT_PCR was applied to examine the expression status of VEGF and Sp1. RESULTS: Western blot and RT_PCR results proved that PD98059 inhibited the phosphorylation of ERK1/2. The expression of VEGF gene was decreased associated with the inhibition of ERK1/2 kinase. The transcription activity of Sp1 was down_regulated by PD98059. SiRNA targeting Sp1 effectively decreased the expression of itself and VEGF. CONCLUSION: In lung cancer cells the expression of VEGF might be regulated by ERK1/2 signal pathway, and partly depended on the activity of transcription factor Sp1.

Key words: lung cancer, VEGF, ERK1/2, Sp1